Business
Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition
NEWTON, Mass., Nov. 18, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer
About this update from Karyopharm Therapeutics Inc.
[{"type":"text","content":"NEWTON, Mass., Nov. 18, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced abstracts detailing selinexor data have been selected to be presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 7-10, 2024 in San Diego, CA.\n\n \n \n \n \n \n \n\n \n\"We are pleased to share presentations on selinexor at this year's annual meeting,\" said Reshma Rangwala, MD, PhD, Chief Medical Officer and Head of Research at Karyopharm. \"The data being presented demonstrate our commitment, as well as that of our partners to our ongoing work in multiple myeloma and myelofibrosis.\"\nDetails for the ASH 2024 selected Karyopharm abstracts are as follows:\nAbstract Title\nPresentation Type\nAbstract #\nSession Date/Time\nMultiple Myeloma\nEfficacy and Safety of Selinexor, Pomalidomide, and Dexamethasone (SPd) for Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM)\nPoster\n1996\nSaturday, December 7, 2024 \n5:30pm - 7:30pm PST/ 8:30pm - 10:30pm EST\nMyelofibrosis\nSelinexor Depletes Ruxolitinib Refractory Myelofibrosis Hematopoietic Stem Cells By Inducing Apoptosis and Blunting the Pro-Inflammatory Milieu\nPoster\n1377\nSaturday, December 7, 2024 \n5:30pm - 7:30pm PST/ 8:30pm - 10:30pm EST\nDetails for a selected partner presentation on Antengene's latest data are as follows:\nAbstract Title\nPresentation Type\nAbstract #\nSession Date/Time\nMultiple Myeloma\nWeekly Selinexor, Bortezomib and Dexamethasone (SVd) Versus Twice Weekly Bortezomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma: Primary Analysis of Phase 3 Bench Study\nPoster\n4748\nMonday, December 9, 2024\n6:00pm - 8:00pm PST/\n9:00pm - 11:00pm EST\nAbout XPOVIO® (selinexor)\nXPOVIO is a first-in-class, oral exportin 1 (XPO1) inhibitor and the first of Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds for the treatment of cancer. XPOVIO functions by selectively binding to and inhibiting the nuclear export protein XPO1. XPOVIO is approved in the U.S. and marketed by Karyopharm in multiple oncology indications, including: (i) in combination with VELCADE® (bortezomib) and dexamethasone (XVd) in patients with multiple myeloma after at least one prior the...